Molecular therapy for Pulmonary Hypertension (PAH): Resistin inhibits pulmonary hypertension via induction of PDLIM5, 8/February/2015, 14.25

Regulation of tRNA synthesis: MiRNA-429 increases the expression of RNA polymerase III via down regulation of its target gene, 8/February/2015, 14.18
February 8, 2015
MiRNA-based therapy for cancer: ID-1 suppresses the expression of tumor suppressor KRIT1/CCM1 via up regulation of its target gene, 8/February/2015, 14.28 am
February 8, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that Resistin, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “Resistin or its activators may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How Resistin  increases the expression of PDLIM5

To citeBoominathan, Molecular therapy for Pulmonary Hypertension (PAH): Resistin inhibits pulmonary hypertension via induction of PDLIM5, 8/February/2015,  14.25,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.